After the Corona 19 crisis, the US pharmaceutical industry had a feast of money thanks to capital investments, both unquestioned and unquestionable.

The New York Times (NYT) reported that since March, when Corona 19 began in earnest, insiders such as executives and major shareholders of 11 US pharmaceutical companies have earned at least US$1 billion and KRW 1.2 trillion in our money.

For the pharmaceutical company Modena, which is developing a Corona19 vaccine in collaboration with the National Institute of Allergic and Infectious Diseases (NIAID), its share price has more than tripled since January, increasing its corporate value to $30 billion.

Modena officials sold $240 million and held approximately 300 billion won worth of stock to earn cash.

Vaxart, a pharmaceutical company with only 15 employees, surged in the news that the Trump administration was selected as a candidate for the'high-speed operation' announced for vaccine development.

The stock price has risen 36 times since January, with so-called'coins', which refers to less than $1 per share, which was only 35 cents per share (KRW 420).

The New York Times reported that the U.S. Department of Health reported concerns to the Securities and Exchange Commission (SEC) about uncertain companies among some pharmaceutical companies that have made a fortune in the stock market through the development of the Corona 19 vaccine.